Advertisement

Topics

Milestone Pharmaceuticals Raises $55M to Advance Etripamil into Phase III Development

16:00 EDT 3 Aug 2017 | Drug Discovery Development

Etripamil is a novel, potent, short-acting calcium channel blocker developed as a fast-acting nasal spray.
Contributed Author: 
Milestone Pharma
Topics: 

Original Article: Milestone Pharmaceuticals Raises $55M to Advance Etripamil into Phase III Development

NEXT ARTICLE

More From BioPortfolio on "Milestone Pharmaceuticals Raises $55M to Advance Etripamil into Phase III Development"

Quick Search
Advertisement
 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...